132 related articles for article (PubMed ID: 34872789)
1. Corrigendum to "Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors" [Canc. Lett. 507 (2021) 13-25].
Prelowska MK; Mehlich D; Ugurlu MT; Kedzierska H; Cwiek A; Kosnik A; Kaminska K; Marusiak AA; Nowis D
Cancer Lett; 2022 Feb; 526():363. PubMed ID: 34872789
[No Abstract] [Full Text] [Related]
2. Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors.
Prelowska MK; Mehlich D; Ugurlu MT; Kedzierska H; Cwiek A; Kosnik A; Kaminska K; Marusiak AA; Nowis D
Cancer Lett; 2021 Jun; 507():13-25. PubMed ID: 33713737
[TBL] [Abstract][Full Text] [Related]
3. Corrigendum to "Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3" [Canc Lett 379 (2016) 124-133].
Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
Cancer Lett; 2020 Nov; 493():13-15. PubMed ID: 32823017
[No Abstract] [Full Text] [Related]
4. Corrigendum to " 2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inhibitors via repressing STAT3 signaling" [Canc. Lett. 471 (2020) 135-146].
Yue Y; Qian W; Li J; Wu S; Zhang M; Wu Z; Ma Q; Wang Z
Cancer Lett; 2022 Nov; 549():215913. PubMed ID: 36152564
[No Abstract] [Full Text] [Related]
5. The role of the glutamine transporter ASCT2 in antineoplastic therapy.
Teixeira E; Silva C; Martel F
Cancer Chemother Pharmacol; 2021 Apr; 87(4):447-464. PubMed ID: 33464409
[TBL] [Abstract][Full Text] [Related]
6. High-affinity glutamate transporter GLAST/EAAT1 regulates cell surface expression of glutamine/neutral amino acid transporter ASCT2 in human fetal astrocytes.
Gegelashvili M; Rodriguez-Kern A; Pirozhkova I; Zhang J; Sung L; Gegelashvili G
Neurochem Int; 2006; 48(6-7):611-5. PubMed ID: 16516348
[TBL] [Abstract][Full Text] [Related]
7. Glutamine transporter ASCT2 was down-regulated in ischemic injured human intestinal epithelial cells and reversed by epidermal growth factor.
Huang Q; Li N; Zhu W; Li Q; Li J
JPEN J Parenter Enteral Nutr; 2007; 31(2):86-93. PubMed ID: 17308248
[TBL] [Abstract][Full Text] [Related]
8. Targeting of glutamine transporter ASCT2 and glutamine synthetase suppresses gastric cancer cell growth.
Ye J; Huang Q; Xu J; Huang J; Wang J; Zhong W; Chen W; Lin X; Lin X
J Cancer Res Clin Oncol; 2018 May; 144(5):821-833. PubMed ID: 29435734
[TBL] [Abstract][Full Text] [Related]
9. Structural characterisation reveals insights into substrate recognition by the glutamine transporter ASCT2/SLC1A5.
Scopelliti AJ; Font J; Vandenberg RJ; Boudker O; Ryan RM
Nat Commun; 2018 Jan; 9(1):38. PubMed ID: 29295993
[TBL] [Abstract][Full Text] [Related]
10. Glutamine-β-cyclodextrin for targeted doxorubicin delivery to triple-negative breast cancer tumors via the transporter ASCT2.
Zhou P; Liang X; Zhou C; Qin J; Hou C; Zhu Z; Zhang W; Wang S; Zhong D
J Mater Chem B; 2019 Sep; 7(35):5363-5375. PubMed ID: 31403158
[TBL] [Abstract][Full Text] [Related]
11. Molecular identification and characterisation of the glycine transporter (GLYT1) and the glutamine/glutamate transporter (ASCT2) in the rat lens.
Lim J; Lorentzen KA; Kistler J; Donaldson PJ
Exp Eye Res; 2006 Aug; 83(2):447-55. PubMed ID: 16635486
[TBL] [Abstract][Full Text] [Related]
12. Novel alanine serine cysteine transporter 2 (ASCT2) inhibitors based on sulfonamide and sulfonic acid ester scaffolds.
Ndaru E; Garibsingh RA; Shi Y; Wallace E; Zakrepine P; Wang J; Schlessinger A; Grewer C
J Gen Physiol; 2019 Mar; 151(3):357-368. PubMed ID: 30718375
[TBL] [Abstract][Full Text] [Related]
13. The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).
Cormerais Y; Massard PA; Vucetic M; Giuliano S; Tambutté E; Durivault J; Vial V; Endou H; Wempe MF; Parks SK; Pouyssegur J
J Biol Chem; 2018 Feb; 293(8):2877-2887. PubMed ID: 29326164
[TBL] [Abstract][Full Text] [Related]
14. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.
van Geldermalsen M; Wang Q; Nagarajah R; Marshall AD; Thoeng A; Gao D; Ritchie W; Feng Y; Bailey CG; Deng N; Harvey K; Beith JM; Selinger CI; O'Toole SA; Rasko JE; Holst J
Oncogene; 2016 Jun; 35(24):3201-8. PubMed ID: 26455325
[TBL] [Abstract][Full Text] [Related]
15. Structure activity relationships of benzylproline-derived inhibitors of the glutamine transporter ASCT2.
Singh K; Tanui R; Gameiro A; Eisenberg G; Colas C; Schlessinger A; Grewer C
Bioorg Med Chem Lett; 2017 Feb; 27(3):398-402. PubMed ID: 28057420
[TBL] [Abstract][Full Text] [Related]
16. Glutamine availability up-regulates expression of the amino acid transporter protein ASCT2 in HepG2 cells and stimulates the ASCT2 promoter.
Bungard CI; McGivan JD
Biochem J; 2004 Aug; 382(Pt 1):27-32. PubMed ID: 15175006
[TBL] [Abstract][Full Text] [Related]
17. ASCT2 regulates glutamine uptake and cell growth in endometrial carcinoma.
Marshall AD; van Geldermalsen M; Otte NJ; Lum T; Vellozzi M; Thoeng A; Pang A; Nagarajah R; Zhang B; Wang Q; Anderson L; Rasko JEJ; Holst J
Oncogenesis; 2017 Jul; 6(7):e367. PubMed ID: 28759021
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of glucose metabolism prevents glycosylation of the glutamine transporter ASCT2 and promotes compensatory LAT1 upregulation in leukemia cells.
Polet F; Martherus R; Corbet C; Pinto A; Feron O
Oncotarget; 2016 Jul; 7(29):46371-46383. PubMed ID: 27344174
[TBL] [Abstract][Full Text] [Related]
19. Sorting nexin 27 (SNX27) regulates the trafficking and activity of the glutamine transporter ASCT2.
Yang Z; Follett J; Kerr MC; Clairfeuille T; Chandra M; Collins BM; Teasdale RD
J Biol Chem; 2018 May; 293(18):6802-6811. PubMed ID: 29563155
[TBL] [Abstract][Full Text] [Related]
20. Topotecan induces hepatocellular injury via ASCT2 mediated oxidative stress.
Zhou G; Qin M; Zhang X; Yang J; Yu H
Gastroenterol Hepatol; 2021 Jan; 44(1):1-12. PubMed ID: 33039171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
